SLS SELLAS Life Sciences Group, Inc. - Common Stock
About SELLAS Life Sciences Group, Inc. - Common Stock Company overview from Wikipedia
Galena Biopharma, Inc. was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc..
Read more
Galena Biopharma, Inc. (originally RXi Pharmaceuticals) was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc. (Nasdaq: SLS).
History
In November 2006, Argonaut Pharmaceuticals, Inc. changed the name to RXi Pharmaceuticals Corporation. RXi was a subsidiary of CytRx Corp., which provided $15 million in financing in April 2007. RXi was founded in part by Nobel Prize winner Craig Mello. In September 2007, RXi signed a licensing deal with TriLink Biotechnologies, a competitor in the RNA interference (RNAi) field, in which RXi would pay TriLink to use three of TriLink's technologies.
In March 2011, the company announced the planned acquisition of Arizona-based Apthera, Inc. for $7 million. The acquisition included the breast cancer drug NeuVax. In June 2011, NeuVax was approved by the United States Food and Drug Administration to start a stage three clinical trial.
In September 2011, the company separated its cancer therapies division. It was renamed Galena Biopharma Inc and moved to Lake Oswego, Oregon. RXi became a subsidiary of Galena and retained RNAi technologies. RXi Pharmaceuticals remained in Massachusetts as a publicly traded company. In January 2014, Galena bought Mills Pharmaceuticals. In April 2014, the company headquarters moved to Portland.
In November 2011, the company partnered with Genentech to combine drugs from each company for a cancer treatment. Galena is currently studying the combination of NeuVax and Herceptin in phase II trials.
Leadership
In March 2011, president and CEO Noah Beerman were replaced by Mark Ahn, and in August 2014, Ahn resigned and was replaced by Mark Schwartz. On January 31, 2017, Galena announced the resignation of Mark Schwartz effective that day, and reported in the same press release that it would be exploring strategic alternatives to maximize shareholder value going forward.
Stock
RXi went public in March 2008. CytRx retained 49% ownership of RXi's stock and gave shares of RXi to existing shareholders. Trading began on the Nasdaq market on March 12, 2008, under the ticker symbol of RXII. Fidelity Investments invested $8.5 million in the company in May 2008, followed by a $25 million private-equity investment by Yorkville in February 2009. In 2010, RXi received a National Institutes of Health grant of $600,000. By August 2010, the company had 30 employees. In April 2011, RXi raised about $12 million from a stock offering and received $580,000 in grants from the National Institutes of Health. The company reported a loss of $11.5 million loss for 2011.
In November 2012, an anonymous internet report caused Galena stock to decline. The company filed a lawsuit claiming the report was false and attempted to manipulate the stock. In 2014, Galena's involvement in a fraudulent stock promotion scheme was exposed. On February 1, 2014, analyst Matt Gravitt published an article that revealed Galena had paid MissionIR, DreamTeam brand, to promote Galena's stock. Galena's stock fell 20% following this revelation that received a heated response, and was one of the three most read articles in Seeking Alpha's history. Over the next few weeks, more revelations came out and the company admitted their stock promotion relationship and insider selling. Galena then disclosed that the SEC was investigation their relationship with The DreamTeam Group. By March 2014, five lawsuits were filed against Galena and several of its officers alleging that the company used misleading articles to boost stock prices. Motley Fool, discussing the 23% stock price drop during March 2015, noted there was stock dilution from the offering and also that Abstral's sales were below Galena's estimates from late 2013. Discussing the Motley Fool article, Portland Business Journal also noted the ongoing insider-trading lawsuits as a factor in the stock price. A few days later, Zacks Investment Research said Galena could be a "great candidate" to beat its earnings. In response, Galena's CEO said there were many positive aspects to the company, and that the lawsuits weren't a worry as they should get covered under Directors and officers liability insurance. The company moved to San Ramon, California, in the Bay Area in 2015.
Stock promotion scandal
The revelation that Galena was engaging in fraudulent stock promotion without adequate disclosure led to the investigation of other biotech companies who engaged in similar activities. Richard Pearson, an investor who went undercover to investigate the stock promotion firms, wrote an exposé on DreamTeam and its ties to articles about Galena, CytRx, and other companies on media websites. In April 2017, the Securities and Exchange Commission announced enforcement actions against 27 individuals and entities behind various alleged stock promotion schemes. Fraud charges were filed against three public companies, seven stock promotion or communications firms, and two company CEOs; also on this hit list are six individuals and nine writers.
Merger with Sellas Life Sciences
In 2017, Galena Biopharma Inc. announced a merger "with privately-held oncology company Sellas Life Sciences Group Ltd. in an all-stock transaction." The combined company was Sellas Life Science Group. The newly merged companies focused on the development of novel treatments for cancer.
Products
Galena acquired the experimental breast cancer drug NeuVax in 2011 and are currently in phase II trials to combine the drug with Genentech's Herceptin.
In 2013, Galena began selling its first developed drug, an analgesic for cancer pain named Abstral Sublingual.
Anagrelide controlled-released (GALE-401) was approved by the FDA for phase III clinical trials for the treatment of essential thrombocytosis in December 2016.
GALE-301 and GALE-302 are immunotherapies in phase I and II trials for ovarian and breast cancers.
== References ==
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
SLS Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
SLS Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Financial Health Debt, liquidity, solvency — balance sheet strength
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
SLS Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
- Strong Buy 1 16.7%
- Buy 4 66.7%
- Hold 1 16.7%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
2 analysts · 2026-08-14Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| March 31, 2026 | $-0.05 | $-0.04 | -0.01% |
| Dec. 31, 2025 | $-0.05 | $-0.07 | 0.02% |
| Sept. 30, 2025 | $-0.06 | $-0.07 | 0.01% |
| June 30, 2025 | $-0.07 | $-0.08 | 0.01% |
| March 31, 2025 | $-0.07 | $-0.11 | 0.04% |
| Dec. 31, 2024 | $-0.08 | $-0.11 | 0.03% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| SLS | $577M | -15.1 | — | — | -55.4% | — |
| IRON | $3.01B | -13.2 | — | — | -31.3% | — |
| BEAM | $2.82B | -34.2 | 120.0% | -57.2% | -7.0% | — |
| NRIX | $1.80B | -5.8 | 53.9% | -314.9% | -53.6% | — |
| RARE | $2.22B | -3.9 | 20.2% | -85.4% | -1613.2% | — |
| KOD | $1.73B | -6.5 | — | — | -202.0% | — |
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | — |
| PGEN | $1.48B | -3.1 | 146.7% | -2588.2% | 3159.1% | — |
| CDNA | $959M | -47.1 | 13.8% | -5.6% | -6.8% | — |
| COAG | — | — | — | — | — | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 15
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $0 | $1M | $8M | $2M | $0 | · | · | · | · | $9M | |
| Cost of Revenue | $0 | $0 | $0 | $100.0K | $200.0K | $0 | · | · | · | · | · | $1M | |
| R&D Expense | · | · | · | · | $16M | $9M | $7M | $9M | $6M | $11M | · | · | |
| SG&A Expense | $12M | $12M | $14M | $13M | $11M | $10M | $10M | $13M | $15M | $5M | · | · | |
| Operating Expenses | $28M | $32M | $38M | $43M | $33M | $19M | $20M | $31M | $23M | $32M | $34M | $44M | |
| Operating Income | $-28M | $-32M | $-38M | $-42M | $-25M | $-17M | $-20M | · | $-23M | $-16M | $-34M | $-44M | |
| Other Non-op | $1M | $632.0K | $529.0K | $649.0K | $4M | $208.0K | $-19M | $-29M | $-24M | $5M | $509.0K | $170.0K | |
| Pretax Income | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-29M | $-24M | $-18M | $-39M | $-28M | |
| Income Tax | $0 | $0 | $0 | $0 | $-237.0K | $-17.0K | $-81.0K | $-1M | $300.0K | $1.0K | $365.0K | $0 | |
| Net Income | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-28M | $-24M | $-18M | $-64M | $-37M | |
| EPS (Basic) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · | |
| EPS (Diluted) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · | |
| Shares (Basic) | 109,051,215 | 61,202,412 | 27,777,111 | 19,395,709 | 15,481,113 | 7,977,104 | · | · | · | · | · | · | |
| Shares (Diluted) | 109,051,215 | 61,202,412 | 27,777,111 | 19,395,709 | 15,481,113 | 7,977,104 | · | · | · | · | · | · | |
| EBITDA | $-28M | $-32M | $-38M | $-42M | $-25M | $-17M | · | · | $-23M | $-32M | · | · |
Balance Sheet 22
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $72M | $14M | $3M | $17M | $21M | $35M | $7M | $5M | $2M | $6M | $1M | $24M | |
| Receivables | · | · | · | · | $0 | · | · | · | · | · | · | $2M | |
| Inventory | · | · | · | · | · | · | · | · | · | · | $0 | $655.0K | |
| Prepaid Expense | $3M | $2M | $542.0K | $531.0K | $2M | $395.0K | $557.0K | $387.0K | $337.0K | $332.0K | $1M | $1M | |
| Current Assets | $75M | $16M | $3M | $18M | $23M | $37M | $8M | $6M | $13M | $6M | $54M | $52M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | $199.0K | $335.0K | $285.0K | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $6M | $6M | |
| Total Assets | $78M | $19M | $6M | $21M | $26M | $46M | $17M | $17M | $34M | $6M | $82M | $80M | |
| Accounts Payable | $3M | $4M | $6M | $3M | $2M | $5M | $4M | $4M | $12M | $840.0K | $2M | $2M | |
| Accrued Liabilities | $4M | $5M | $8M | $6M | $3M | $2M | $1M | $2M | $3M | $4M | $5M | $9M | |
| Current Liabilities | $7M | $10M | $14M | $16M | $5M | $12M | $5M | $6M | $25M | $6M | $57M | $27M | |
| Capital Leases | $457.0K | $457.0K | $460.0K | $573.0K | $610.0K | $825.0K | $0 | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | $0 | $239.0K | $262.0K | $357.0K | $2M | · | · | · | |
| Total Liabilities | $7M | $10M | $14M | $16M | $6M | $18M | $11M | $12M | $31M | $11M | $69M | $43M | |
| Long-term Debt | · | · | · | · | · | · | · | $0 | $11M | · | $5M | $8M | |
| Total Debt | · | · | · | · | · | · | · | · | $11M | $16M | · | · | |
| Common Stock | $15.0K | $7.0K | $3.0K | $2.0K | $2.0K | $1.0K | $1.0K | $1.0K | $1.0K | $2.0K | $15.0K | $12.0K | |
| Retained Earnings | $-275M | $-248M | $-217M | $-180M | $-139M | $-118M | $-101M | $-82M | $-54M | $-30M | · | · | |
| Treasury Stock | · | · | · | · | · | · | · | · | · | $4M | $4M | $4M | |
| Stockholders' Equity | $71M | $9M | $-8M | $5M | $20M | $28M | $6M | $5M | $2M | $-5M | $-12M | $37M | |
| Liabilities + Equity | $78M | $19M | $6M | $21M | $26M | $46M | $17M | $17M | $34M | $6M | $82M | $80M | |
| Shares Outstanding | 153,103,459 | 73,977,459 | 32,132,890 | 21,005,405 | 15,895,637 | 14,254,554 | 5,080,100 | 440,529 | 5,766,891 | 1,268,489 | 8,095,337 | 109,425,701 |
Cash Flow 17
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | $3.0K | $107.0K | $86.0K | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $1M | $578.0K | $573.0K | $395.0K | $3M | $354.0K | $2M | $5M | |
| Deferred Tax | · | · | · | $0 | $-239.0K | $-22.0K | $-95.0K | $-1M | $39.0K | $-41.0K | $365.0K | $0 | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $0 | $2M | · | · | $440.0K | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | $-24M | · | · | |
| Operating Cash Flow | $-28M | $-35M | $-31M | $-24M | $-26M | $-10M | $-18M | $-30M | $-11M | $-12M | $-48M | $-43M | |
| CapEx | · | · | · | · | · | · | · | · | · | $6.0K | $153.0K | $57.0K | |
| Investing Cash Flow | · | $0 | $-6M | $-4M | $0 | · | · | $0 | $12M | $-85.0K | $10M | $-6M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | $2M | $0 | $0 | |
| Net Debt Issued | · | · | · | · | · | · | $0 | · | · | $18M | · | · | |
| Stock Issued | · | $0 | $289.0K | $1M | $9M | $30M | $16M | $22M | $6M | $34M | $47M | $11M | |
| Net Stock Activity | · | $0 | $289.0K | $1M | $9M | $30M | $16M | · | $6M | $34M | · | · | |
| Dividends Paid | · | · | · | · | · | · | $0 | $487.0K | $0 | · | · | · | |
| Financing Cash Flow | $86M | $47M | $22M | $24M | $12M | $38M | $20M | $23M | $6M | $16M | $44M | $24M | |
| Net Change in Cash | $58M | $11M | $-15M | $-4M | $-14M | $28M | $2M | $-7M | $7M | $5M | $6M | $-24M | |
| Taxes Paid | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-45M | · | · |
Profitability 7
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | -4195.0% | -332.8% | -893.8% | · | · | 4986.8% | · | · | · | |
| Net Margin | · | · | · | -4130.1% | -272.4% | -881.9% | -16349.1% | · | 5141.6% | · | · | · | |
| Pretax Margin | · | · | · | -4130.1% | -275.5% | -882.8% | -16417.0% | · | 5086.8% | · | · | · | |
| EBITDA Margin | · | · | · | -4195.0% | -332.8% | -893.8% | · | · | 4986.8% | · | · | · | |
| ROA | -54.9% | -240.8% | -274.9% | -174.9% | -57.2% | -53.5% | -115.1% | · | -118.9% | -31.8% | · | · | |
| ROE | -55.4% | -243.6% | 632.7% | -473.4% | -88.2% | -93.3% | -340.3% | · | 1623.1% | -287.3% | · | · | |
| ROIC | -39.9% | -332.9% | 474.8% | -864.8% | -122.9% | -60.7% | · | · | -178.3% | -72.3% | · | · |
Liquidity & Solvency 4
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.7 | 1.7 | 0.2 | 1.1 | 4.6 | 3.0 | 1.6 | · | 0.5 | 1.2 | · | · | |
| Quick Ratio | 10.2 | 1.5 | 0.2 | 1.1 | 4.3 | 2.9 | 1.4 | · | 0.1 | 0.6 | · | · | |
| Debt / Equity | · | · | · | · | · | · | · | · | 5.3 | 0.6 | · | · | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | 1.3 | · | · | · |
Efficiency 1
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | · | -0.0 | · | · | · |
Growth Rates 1
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | · | -86.8% | 300.0% | · | · | · | · | · | · | · |
Valuation (TTM) 17
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | $0 | $1M | $8M | $2M | $0 | $10M | $10M | $10M | $10M | $9M | |
| Net Income TTM | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-28M | $-24M | $-18M | $-64M | $-37M | |
| Market Cap | $577M | $77M | $34M | $50M | $88M | $83M | $22M | · | $2.25B | $44.20B | · | · | |
| Enterprise Value | · | · | · | · | · | · | · | · | $2.26B | $44.20B | · | · | |
| P/E | -15.1 | -2.1 | -0.8 | -1.1 | -4.1 | -2.8 | · | · | · | · | · | · | |
| P/S | · | · | · | 49.6 | 11.6 | 43.6 | · | · | 223.1 | 4384.0 | · | · | |
| P/B | 8.1 | 8.1 | -4.3 | 10.2 | 4.3 | 3.0 | 3.6 | · | 1086.5 | 1542.5 | · | · | |
| P / Tangible Book | 8.4 | 10.2 | · | 16.9 | 4.8 | 3.2 | · | · | · | · | · | · | |
| P / Cash Flow | -20.3 | -2.2 | -1.1 | -2.1 | -3.4 | -8.0 | -1.2 | · | -204.7 | -984.2 | · | · | |
| P / FCF | · | · | · | · | · | · | · | · | · | -984.0 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | -98.0 | -1393.3 | · | · | |
| EV / FCF | · | · | · | · | · | · | · | · | · | -984.0 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | 223.9 | 4383.9 | · | · | |
| Dividend Yield | · | · | · | · | · | · | 0.00% | · | 0.00% | · | · | · | |
| Earnings Yield | -6.6% | -48.1% | -126.4% | -90.2% | -24.2% | -36.3% | · | · | · | · | · | · | |
| Payout Ratio | · | · | · | · | · | · | 0.00% | · | · | · | · | · | |
| Annual Payout | · | · | · | · | · | · | $0 | $487.0K | $0 | · | · | · |
Income Statement 12
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| SG&A Expense | $4M | $4M | $4M | $3M | $3M | $3M | $2M | $3M | $2M | $5M | $3M | $4M | $3M | $4M | $4M | $3M | |
| Operating Expenses | $11M | $9M | $8M | $7M | $7M | $6M | $7M | $7M | $8M | $10M | $8M | $9M | $9M | $11M | $9M | $7M | |
| Operating Income | $-11M | $-9M | $-8M | $-7M | $-7M | $-6M | $-7M | $-7M | $-8M | $-10M | $-8M | $-9M | $-9M | $-11M | $-9M | $-7M | |
| Other Non-op | $1M | $845.0K | $597.0K | $292.0K | $272.0K | $250.0K | $181.0K | $221.0K | $151.0K | $79.0K | $41.0K | $94.0K | $210.0K | $184.0K | $325.0K | $124.0K | |
| Net Income | $-10M | $-8M | $-8M | $-7M | $-7M | $-6M | $-7M | $-7M | $-7M | $-10M | $-8M | $-9M | $-9M | $-11M | $-9M | $-7M | |
| EPS (Basic) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.06 | $-0.10 | $-0.13 | $-0.21 | $-0.23 | $-0.33 | $-0.31 | $-0.47 | $-0.33 | $-0.34 | |
| EPS (Diluted) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.06 | $-0.10 | $-0.13 | $-0.21 | $-0.23 | $-0.33 | $-0.31 | $-0.47 | $-0.33 | $-0.34 | |
| Shares (Basic) | 189,183,620 | 172,481,541 | -185,663,932 | 108,396,260 | 98,558,567 | 87,760,320 | -109,495,111 | 68,254,021 | 57,630,506 | 44,812,996 | -52,473,798 | 28,355,427 | 28,347,920 | 23,547,562 | -37,350,745 | 20,562,351 | |
| Shares (Diluted) | 189,183,620 | 172,481,541 | -185,663,932 | 108,396,260 | 98,558,567 | 87,760,320 | -109,495,111 | 68,254,021 | 57,630,506 | 44,812,996 | -52,473,798 | 28,355,427 | 28,347,920 | 23,547,562 | -37,350,745 | 20,562,351 | |
| EBITDA | $-11M | $-9M | · | $-7M | $-7M | $-6M | · | $-7M | $-8M | $-10M | · | $-9M | $-9M | $-11M | · | $-7M |
Balance Sheet 15
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $138M | $107M | $72M | $44M | $25M | $28M | $14M | $21M | $9M | $18M | $3M | $4M | $14M | $24M | $17M | $21M | |
| Prepaid Expense | $4M | $4M | $3M | $5M | $4M | $3M | $2M | $3M | $3M | $3M | $542.0K | $1M | $2M | $2M | $531.0K | $1M | |
| Current Assets | $143M | $111M | $75M | $49M | $29M | $32M | $16M | $24M | $12M | $22M | $3M | $5M | $16M | $26M | $18M | $23M | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Total Assets | $145M | $114M | $78M | $52M | $32M | $35M | $19M | $27M | $15M | $24M | $6M | $8M | $19M | $29M | $21M | $26M | |
| Accounts Payable | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $5M | $6M | $7M | $6M | $4M | $4M | $3M | $3M | $2M | |
| Accrued Liabilities | $4M | $2M | $4M | $3M | $2M | $3M | $5M | $5M | $5M | $7M | $8M | $7M | $6M | $6M | $6M | $5M | |
| Current Liabilities | $8M | $6M | $7M | $6M | $6M | $7M | $10M | $11M | $12M | $14M | $14M | $12M | $13M | $16M | $16M | $13M | |
| Capital Leases | $157.0K | $309.0K | $457.0K | $0 | $157.0K | $309.0K | $457.0K | $0 | $161.0K | $313.0K | $460.0K | $178.0K | $302.0K | $422.0K | $573.0K | $680.0K | |
| Total Liabilities | $8M | $7M | $7M | $6M | $6M | $7M | $10M | $11M | $12M | $15M | $14M | $12M | $14M | $16M | $16M | $13M | |
| Common Stock | $20.0K | $18.0K | $15.0K | $12.0K | $10.0K | $9.0K | $7.0K | $6.0K | $5.0K | $5.0K | $3.0K | $3.0K | $3.0K | $3.0K | $2.0K | $2.0K | |
| Retained Earnings | $-293M | $-283M | $-275M | $-267M | $-261M | $-254M | $-248M | $-241M | $-234M | $-227M | $-217M | $-209M | $-200M | $-191M | $-180M | $-171M | |
| Stockholders' Equity | $138M | $107M | $71M | $46M | $26M | $28M | $9M | $16M | $3M | $10M | $-8M | $-4M | $5M | $13M | $5M | $13M | |
| Liabilities + Equity | $145M | $114M | $78M | $52M | $32M | $35M | $19M | $27M | $15M | $24M | $6M | $8M | $19M | $29M | $21M | $26M | |
| Shares Outstanding | 201,918,874 | 181,332,574 | 153,103,459 | 125,078,525 | 100,367,113 | 90,896,125 | 73,977,459 | 64,381,979 | 57,754,928 | 56,267,670 | 32,132,890 | 28,393,958 | 28,347,920 | 28,347,920 | 21,005,405 | 20,588,247 |
Cash Flow 7
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $1M | $798.0K | $447.0K | $503.0K | $501.0K | $505.0K | $373.0K | $381.0K | $334.0K | $476.0K | $497.0K | $543.0K | $514.0K | $540.0K | $446.0K | $455.0K | |
| Operating Cash Flow | $-8M | $-9M | $-5M | $-7M | $-7M | $-9M | $-7M | $-8M | $-10M | $-11M | $-5M | $-7M | $-8M | $-12M | $-5M | $-6M | |
| Investing Cash Flow | · | · | · | · | · | · | · | $0 | · | · | $0 | $-3M | · | · | $0 | $0 | |
| Stock Issued | · | · | · | · | · | · | · | $0 | $0 | $0 | $21.0K | $0 | $0 | $268.0K | $929.0K | $69.0K | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $268.0K | · | · | |
| Financing Cash Flow | $39M | $44M | $32M | $26M | $4M | $24M | $8.0K | $20M | $414.0K | $27M | $3M | $54.0K | $-29.0K | $19M | $929.0K | $107.0K | |
| Net Change in Cash | $31M | $35M | $27M | $19M | $-3M | $15M | $-7M | $12M | $-9M | $16M | $-1M | $-10M | $-10M | $7M | $-4M | $-6M |
Profitability 5
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | · | · | · | · | -12208.9% | · | · | · | · | · | · | |
| Net Margin | · | · | · | · | · | · | · | · | · | -12108.9% | · | · | · | · | · | · | |
| EBITDA Margin | · | · | · | · | · | · | · | · | · | -12208.9% | · | · | · | · | · | · | |
| ROA | -10.8% | -11.3% | · | -17.4% | -27.8% | -19.6% | · | -41.1% | -44.4% | -35.7% | · | -54.4% | -34.8% | -43.9% | · | -22.0% | |
| ROE | -11.7% | -12.4% | · | -22.1% | -45.4% | -31.1% | · | -117.8% | -192.6% | -83.7% | · | -211.3% | -74.0% | -129.1% | · | -35.8% |
Liquidity & Solvency 2
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 18.8 | 17.2 | · | 8.3 | 4.9 | 4.6 | · | 2.3 | 1.0 | 1.5 | · | 0.4 | 1.2 | 1.7 | · | 1.8 | |
| Quick Ratio | 18.3 | 16.6 | · | 7.5 | 4.2 | 4.1 | · | 2.0 | 0.8 | 1.3 | · | 0.3 | 1.0 | 1.5 | · | 1.7 |
Efficiency 1
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | · | · | · | · | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
Valuation (TTM) 9
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $1M | · | $1M | |
| Net Income TTM | $-31M | $-28M | · | $-26M | $-27M | $-30M | · | $-33M | $-35M | $-39M | · | $-36M | $-35M | $-43M | · | $-39M | |
| Market Cap | $2.98B | $767M | · | $201M | $220M | $98M | · | $80M | $69M | $57M | · | $47M | $45M | $41M | · | $42M | |
| P/E | -64.2 | -16.9 | · | -5.4 | -5.9 | -2.1 | · | -1.6 | -1.2 | -0.8 | · | -1.1 | -1.0 | -0.6 | · | -0.9 | |
| P/S | · | · | · | · | · | · | · | · | · | · | · | · | · | 40.5 | · | 41.6 | |
| P/B | 21.7 | 7.1 | · | 4.4 | 8.4 | 3.5 | · | 5.1 | 23.6 | 5.9 | · | -12.2 | 9.2 | 3.1 | · | 3.3 | |
| P / Tangible Book | 22.0 | 7.3 | · | 4.6 | 9.1 | 3.8 | · | 5.8 | 68.8 | 7.3 | · | · | 15.2 | 3.6 | · | 3.9 | |
| P / Cash Flow | · | -86.7 | · | · | · | -10.8 | · | · | · | -5.3 | · | · | · | -3.3 | · | · | |
| Earnings Yield | -1.6% | -5.9% | · | -18.6% | -16.9% | -47.2% | · | -61.6% | -82.3% | -130.7% | · | -88.4% | -97.5% | -158.7% | · | -111.4% |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Income Statement
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $1M | $8M |
| Operating Margin % | — | — | — | -4195.0% | -332.8% |
| Net Income | $-27M | $-31M | $-37M | $-41M | $-21M |
| Diluted EPS | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 |
Balance Sheet
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Current Ratio | 10.7 | 1.7 | 0.2 | 1.1 | 4.6 |
| Quick Ratio | 10.2 | 1.5 | 0.2 | 1.1 | 4.3 |
Latest News Recent headlines mentioning this company
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 232 filers · $1.2B total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 88 (+21 vs prior Q) | 19 (+4 vs prior Q) | 70 (+12 vs prior Q) | 38 (+15 vs prior Q) | +29.5M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| STATE STREET CORP | $191,829,196 | 12,996,558 | 15.97% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $121,417,310 | 8,226,105 | 10.11% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $105,640,272 | 7,157,200 | 8.79% | Call option |
| Anson Funds Management LP | $66,420,000 | 4,500,000 | 5.53% | Shares |
| CITADEL ADVISORS LLC | $64,157,292 | 4,346,700 | 5.34% | Call option |
| GEODE CAPITAL MANAGEMENT, LLC | $61,905,400 | 4,193,009 | 5.15% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $61,832,592 | 4,189,200 | 5.15% | Put option |
| CITADEL ADVISORS LLC | $33,333,984 | 2,258,400 | 2.77% | Put option |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $31,897,821 | 2,161,099 | 2.66% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $30,266,812 | 2,050,597 | 2.52% | Shares |
| JONES FINANCIAL COMPANIES LLLP | $28,553,511 | 2,304,561 | 2.38% | Shares |
| VANGUARD GROUP INC | $27,868,421 | 7,392,154 | 2.32% | Shares |
| Anson Funds Management LP | $27,245,484 | 1,845,900 | 2.27% | Put option |
| PERCEPTIVE ADVISORS LLC | $22,140,000 | 1,500,000 | 1.84% | Put option |
| VANGUARD FIDUCIARY TRUST CO | $19,707,050 | 1,335,166 | 1.64% | Shares |
| Sio Capital Management, LLC | $18,165,132 | 1,230,700 | 1.51% | Put option |
| BNP PARIBAS FINANCIAL MARKETS | $15,823,045 | 1,072,022 | 1.32% | Shares |
| MILLENNIUM MANAGEMENT LLC | $13,372,560 | 906,000 | 1.11% | Put option |
| BARCLAYS PLC | $11,831,616 | 801,600 | 0.98% | Put option |
| Anson Funds Management LP | $11,808,000 | 800,000 | 0.98% | Call option |
| BNP PARIBAS FINANCIAL MARKETS | $11,734,200 | 7,950 | 0.98% | Put option |
| JANE STREET GROUP, LLC | $11,058,192 | 749,200 | 0.92% | Call option |
| MORGAN STANLEY | $9,922,380 | 672,248 | 0.83% | Shares |
| BANK OF AMERICA CORP /DE/ | $9,150,359 | 619,943 | 0.76% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $8,339,518 | 565,008 | 0.69% | Shares |
| JANE STREET GROUP, LLC | $7,462,700 | 505,603 | 0.62% | Shares |
| Balyasny Asset Management L.P. | $7,380,000 | 500,000 | 0.61% | Put option |
| LMR Partners LLP | $6,642,000 | 450,000 | 0.55% | Put option |
| NOMURA HOLDINGS INC | $6,273,000 | 425,000 | 0.52% | Call option |
| DIADEMA PARTNERS LP | $5,904,000 | 400,000 | 0.49% | Call option |
| Swiss National Bank | $5,319,504 | 360,400 | 0.44% | Shares |
| XTX Topco Ltd | $5,300,168 | 359,090 | 0.44% | Shares |
| Ikarian Capital, LLC | $5,235,372 | 354,700 | 0.44% | Put option |
| CITIGROUP INC | $4,659,717 | 315,699 | 0.39% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $4,580,973 | 310,364 | 0.38% | Shares |
| DAGCO, INC. | $4,351,740 | 1,028,780 | 0.36% | Shares |
| Everhart Financial Group, Inc. | $4,251,146 | 288,018 | 0.35% | Shares |
| Rafferty Asset Management, LLC | $3,540,806 | 239,892 | 0.29% | Shares |
| RHUMBLINE ADVISERS | $3,400,726 | 230,402 | 0.28% | Shares |
| Walleye Capital LLC | $3,377,088 | 228,800 | 0.28% | Put option |
| GOLDMAN SACHS GROUP INC | $3,125,991 | 211,788 | 0.26% | Shares |
| TUDOR INVESTMENT CORP ET AL | $3,087,792 | 209,200 | 0.26% | Put option |
| WELLINGTON MANAGEMENT GROUP LLP | $2,992,738 | 202,760 | 0.25% | Shares |
| BOOTHBAY FUND MANAGEMENT, LLC | $2,982,996 | 202,100 | 0.25% | Put option |
| Jefferies Financial Group Inc. | $2,958,775 | 200,459 | 0.25% | Shares |
| Jefferies Financial Group Inc. | $2,953,476 | 200,100 | 0.25% | Put option |
| Mariner, LLC | $2,925,609 | 198,212 | 0.24% | Shares |
| MILLENNIUM MANAGEMENT LLC | $2,895,912 | 196,200 | 0.24% | Call option |
| Bank of New York Mellon Corp | $2,801,212 | 189,784 | 0.23% | Shares |
| ALPS ADVISORS INC | $2,776,459 | 188,107 | 0.23% | Shares |
| JANE STREET GROUP, LLC | $2,405,880 | 163,000 | 0.20% | Put option |
| LPL Financial LLC | $2,297,586 | 155,663 | 0.19% | Shares |
| SIMPLEX TRADING, LLC | $2,274,501 | 154,099 | 0.19% | Shares |
| BlackRock, Inc. | $2,222,708 | 150,590 | 0.19% | Shares |
| WELLS FARGO & COMPANY/MN | $2,208,775 | 149,646 | 0.18% | Shares |
| Vontobel Holding Ltd. | $2,166,207 | 146,762 | 0.18% | Shares |
| TUDOR INVESTMENT CORP ET AL | $2,069,352 | 140,200 | 0.17% | Call option |
| Vanguard Global Advisers, LLC | $1,918,874 | 130,005 | 0.16% | Shares |
| VANGUARD ASSET MANAGEMENT, Ltd | $1,859,598 | 125,989 | 0.15% | Shares |
| Caption Management, LLC | $1,845,000 | 125,000 | 0.15% | Put option |
| PROFUND ADVISORS LLC | $1,780,159 | 120,607 | 0.15% | Shares |
| MetLife Investment Management, LLC | $1,624,810 | 110,082 | 0.14% | Shares |
| Daiwa Securities Group Inc. | $1,589,652 | 107,700 | 0.13% | Put option |
| Daiwa Securities Group Inc. | $1,512,900 | 102,500 | 0.13% | Shares |
| DIADEMA PARTNERS LP | $1,476,000 | 100,000 | 0.12% | Put option |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | $1,467,144 | 99,400 | 0.12% | Shares |
| STATE OF WISCONSIN INVESTMENT BOARD | $1,405,300 | 95,210 | 0.12% | Shares |
| Harvest Investment Services, LLC | $1,394,554 | 94,482 | 0.12% | Shares |
| ORBIMED ADVISORS LLC | $1,365,300 | 92,500 | 0.11% | Put option |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $1,229,582 | 83,305 | 0.10% | Shares |
| Invesco Ltd. | $1,104,816 | 74,852 | 0.09% | Shares |
| Gotham Asset Management, LLC | $1,097,317 | 74,344 | 0.09% | Shares |
| FULCRUM WEALTH ADVISORS, LLC | $1,081,214 | 73,253 | 0.09% | Shares |
| ALLIANCEBERNSTEIN L.P. | $998,534 | 236,060 | 0.08% | Shares |
| NEW YORK STATE COMMON RETIREMENT FUND | $978,588 | 66,300 | 0.08% | Shares |
| Verition Fund Management LLC | $916,596 | 62,100 | 0.08% | Put option |
| OSAIC HOLDINGS, INC. | $889,776 | 60,284 | 0.07% | Shares |
| FIFTH THIRD BANCORP | $888,404 | 60,190 | 0.07% | Shares |
| State of New Jersey Common Pension Fund D | $857,069 | 58,067 | 0.07% | Shares |
| Verition Fund Management LLC | $832,464 | 56,400 | 0.07% | Call option |
| Police & Firemen's Retirement System of New Jersey | $821,630 | 55,666 | 0.07% | Shares |
| ARIZONA STATE RETIREMENT SYSTEM | $731,388 | 49,552 | 0.06% | Shares |
| Caption Management, LLC | $728,745 | 49,373 | 0.06% | Shares |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $722,310 | 48,937 | 0.06% | Shares |
| Russell Investments Group, Ltd. | $704,494 | 47,730 | 0.06% | Shares |
| SIG BROKERAGE, LP | $689,292 | 46,700 | 0.06% | Call option |
| Vanguard Investments Australia, Ltd. | $684,643 | 46,385 | 0.06% | Shares |
| COMMONWEALTH EQUITY SERVICES, LLC | $665,481 | 45,087 | 0.06% | Shares |
| INSTRUMENTAL WEALTH, LLC | $662,931 | 44,914 | 0.06% | Shares |
| Persistent Asset Partners Ltd | $655,647 | 758 | 0.05% | Call option |
| Virtus Investment Advisers, LLC | $616,791 | 41,788 | 0.05% | Shares |
| Accurate Wealth Management, LLC | $614,707 | 47,462 | 0.05% | Shares |
| AXXCESS WEALTH MANAGEMENT, LLC | $610,665 | 41,373 | 0.05% | Shares |
| KLP KAPITALFORVALTNING AS | $600,732 | 40,700 | 0.05% | Shares |
| SJS Investment Consulting Inc. | $590,400 | 40,000 | 0.05% | Shares |
| Wealthfront Advisers LLC | $587,773 | 39,822 | 0.05% | Shares |
| Quantinno Capital Management LP | $546,651 | 37,036 | 0.05% | Shares |
| Visionary Horizons, LLC | $531,360 | 36,000 | 0.04% | Shares |
| Kestra Advisory Services, LLC | $516,305 | 34,980 | 0.04% | Shares |
| NORTHSTAR ASSET MANAGEMENT Co | $509,400 | 45,000 | 0.04% | Shares |
Company insiders 42 insiders · 17 officers · 9 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Andelos M. Stergiou | President and CEO | June 16, 2026 A | 1,759,183 | 0 | 0 | $0 |
| Noah D Beerman | CEO and President | March 15, 2011 A | 92,994 | 0 | 0 | $0 |
| John Thomas Burns | CFO | Jan. 7, 2026 A | 554,327 | 0 | 0 | $0 |
| Gene Mack | CFO and Treasurer | April 20, 2018 A | — | 0 | 0 | $0 |
| Robert Eugene Kennedy | Vice President and CFO | April 13, 2011 A | 379,294 | 0 | 0 | $0 |
| Stephen J. Dipalma | CFO, EVP, Secretary | Jan. 15, 2009 A | — | 0 | 0 | $0 |
| Dragan Cicic | SVP, Chief Development Officer | Jan. 7, 2026 A | 557,805 | 0 | 0 | $0 |
| Robert Francomano | Chief Commercial Officer | Jan. 22, 2024 A | 40,918 | 0 | 0 | $0 |
| Barbara A Wood | EVP, Gen. Counsel, Corp. Sec. | Jan. 22, 2024 A | 117,225 | 0 | 0 | $0 |
| Nicholas J. Sarlis | Chief Medical Officer and SVP | March 14, 2019 A | — | 0 | 0 | $0 |
| Gregory M Torre | CRO and SVP | March 13, 2018 A | — | 0 | 0 | $0 |
| Amy B Tata | Principlw Acctg Officer & Cont | March 15, 2011 A | 14,065 | 0 | 0 | $0 |
| Ramani Varanasi | VP Business Development | March 15, 2011 A | 41,083 | 0 | 0 | $0 |
| Anastasia Khvorova | Chief Science Officer | March 15, 2011 A | 60,559 | 0 | 0 | $0 |
| Pamela Pavco | VP of Pharmaceutical Devlpmt | March 15, 2011 A | 44,940 | 0 | 0 | $0 |
| Konstantinos Andrikopoulos | VP, Legal | April 15, 2010 A | 5,750 | 0 | 0 | $0 |
| Dmitry Samarsky | VP, Technology Development | March 31, 2010 S | 0 | 0 | 0 | $0 |
| Katherine Bach Kalin | Director | Jan. 7, 2026 A | 154,400 | 1 | 0 | $100,806 |
| John Varian | Director | Jan. 7, 2026 A | 72,900 | 0 | 0 | $0 |
| Jane Wasman | Director | Jan. 7, 2026 A | 92,900 | 0 | 0 | $0 |
| David A Scheinberg | Director | Jan. 7, 2026 A | 73,082 | 0 | 0 | $0 |
| Robert L Van Nostrand | Director | Jan. 7, 2026 A | 82,900 | 0 | 0 | $0 |
| Stephen F Ghiglieri | Director | March 14, 2019 A | — | 0 | 0 | $0 |
| Fabio Lopez | Director | June 12, 2018 A | — | 0 | 0 | $0 |
| Irving M. Einhorn | — | Oct. 10, 2017 A | 34,690 | 0 | 0 | $0 |
| William Ashton | — | Oct. 10, 2017 A | 38,154 | 0 | 0 | $0 |
| Richard Chin | — | Oct. 10, 2017 A | 31,339 | 0 | 0 | $0 |
| Rudolph Nisi | — | Oct. 10, 2017 A | 42,918 | 0 | 0 | $0 |
| Sanford Hillsberg | — | Oct. 10, 2017 A | 56,950 | 0 | 0 | $0 |
| Mary Ann Gray | — | Oct. 10, 2017 A | 39,167 | 0 | 0 | $0 |
| Stephen S Galliker | — | Oct. 10, 2017 A | 36,039 | 0 | 0 | $0 |
| Thomas J Knapp | — | Feb. 6, 2017 A | — | 0 | 0 | $0 |
| Bijan Nejadnik | — | Jan. 17, 2017 A | — | 0 | 0 | $0 |
| Ryan Dunlap | — | June 1, 2016 M | 18,702 | 0 | 0 | $0 |
| Mark W. Schwartz | — | Dec. 18, 2015 A | 415,972 | 0 | 0 | $0 |
| Steven A Kriegsman | — | June 19, 2015 A | 5,000 | 0 | 0 | $0 |
| Margaret Kivinski | — | Jan. 16, 2015 A | — | 0 | 0 | $0 |
| Brian L Hamilton | — | June 30, 2014 J | 2,461 | 0 | 0 | $0 |
| Mark J Ahn | — | June 30, 2014 A | 116,225 | 0 | 0 | $0 |
| Rosemary Mazanet | — | Jan. 29, 2013 A | — | 0 | 0 | $0 |
| CYTRX CORP | — | Dec. 29, 2010 S | 0 | 0 | 0 | $0 |
| Tod Woolf | — | Jan. 15, 2009 A | — | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 2 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Equilibria Capital Management Limited (2), EQC Private Markets SAC Fund II Ltd — EQC Biotech Sely S Fund (2), EQC Private Markets SAC Fund Ltd — EQC Biotech Sely I Fund (2), EQC Private Markets SAC Fund Ltd — EQC Biotech Sely II Fund (2), EQC Private Markets II SAC Fund Ltd — EQC Biotech Sely III Fund (2), Varibobi Financial Holdings Ltd. (2), Daniel Tafur (2), Fabio López (2) ×4 filings | Oct. 10, 2018 | — | Initial filing | — | SEC |
| Angelos M. Stergiou, M.D., Sc.D. h.c. | Jan. 8, 2018 | — | Initial filing | M&A / sale | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF ownership Held by 29 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| LABU · Direxion Shares ETF Trust | 0.26% | 268,465 NS | April 30, 2026 | N-PORT |
| CANC · Tema ETF Trust | 0.22% | 40,702 NS | May 31, 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0.05% | 51,293 NS | May 31, 2026 | N-PORT |
| ITWO · ProShares Trust | 0.04% | 8,088 NS | May 31, 2026 | N-PORT |
| RSSL · Global X Funds | 0.03% | 74,459 NS | April 30, 2026 | N-PORT |
| UWM · ProShares Trust | 0.02% | 6,326 NS | May 31, 2026 | N-PORT |
| URTY · ProShares Trust | 0.02% | 6,397 NS | May 31, 2026 | N-PORT |
| HDG · ProShares Trust | 0.01% | 161 NS | May 31, 2026 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0.01% | 64,480 NS | May 31, 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.00% | 3,554 NS | May 31, 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | July 15, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | — | — | July 15, 2026 | Daily |
| VFMO · VANGUARD WELLINGTON FUND | — | — | July 30, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | — | — | July 15, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | — | — | July 15, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | — | — | July 15, 2026 | Daily |
| ITOT · iShares Trust | — | — | July 22, 2026 | Daily |
| IWV · iShares Trust | — | — | Aug. 18, 2026 | Daily |
| IWO · iShares Trust | — | — | Aug. 18, 2026 | Daily |
| IWM · iShares Trust | — | — | Aug. 18, 2026 | Daily |
| IWC · iShares Trust | — | — | Aug. 18, 2026 | Daily |
| ICOP · iShares Trust | — | — | Aug. 18, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | — | — | July 20, 2026 | Daily |
| PICK · iShares, Inc. | — | — | Aug. 14, 2026 | Daily |
| ISCB · iShares Trust | — | — | July 21, 2026 | Daily |
| ISCG · iShares Trust | — | — | July 21, 2026 | Daily |
| ISCF · iShares Trust | — | — | Aug. 10, 2026 | Daily |
| WSML · iShares Trust | — | — | Aug. 10, 2026 | Daily |
| DWAS · Invesco Exchange-Traded Fund Trust … | — | — | July 20, 2026 | Daily |